Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Saigi N, Espelt A, Folch C, Sarasa-Renedo A, Castellano Y, Majo X, Merono M, Brugal MT, Casabona J, REDAN Group. Differences in illegal drug consumption between native and immigrants in a large sample of injected drug users in Catalonia (Spain). Adicciones. 2014;26(1):69-76. doi: 10.20882/adicciones.136
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Leiss JK, Lyden JT, Mathews R, Sitzman KL, Vanderpuije A, Mav D, Kendra MA, Klein C, Humphrey CJ. Blood exposure incidence rates from the North Carolina study of home care and hospice nurses. Am J Ind Med. 2009 Feb 1;52(2):99-104.
Lanes SF, Rothman KJ, Dreyer NA, Soden K. Mortality among workers exposed to glycerol polyglicidyl ether. Am J Ind Med. 1994 May;25(5):689-96. doi: 10.1002/ajim.4700250508
Lanes SF, Rothman KJ, Soden KJ, Amsel J, Dreyer NA. Mortality among synthetic-fiber workers exposed to glycerol polyglycidyl ether. Am J Ind Med. 1994 Jan 1;25(5):689-96.